Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING

HELD ON MONDAY, 18 DECEMBER 2017

The board of directors (the "Board") of Sinopharm Group Co. Ltd. (the "Company") is pleased to announce that the extraordinary general meeting (the "EGM") was held at Meeting Room 1813, Sinopharm Plaza, No. 1001 Zhongshan West Road, Changning District, Shanghai, the People's Republic of China (the "PRC") at 9:30 a.m. on Monday, 18 December 2017. The resolutions proposed at the EGM was duly passed by way of poll.

The poll results in respect of the resolutions proposed at the EGM are as follows:

Ordinary Resolutions

Number of Valid Votes (%)

For

Against

1.

THAT the Procurement Framework Agreement entered into by the Company and China National Pharmaceutical Group Corporation on 27 October 2017 and the annual caps for the continuing connected transactions contemplated thereunder, be and are hereby approved and confirmed; and THAT any one director of the Company be and is hereby authorized to sign or execute such other documents or supplemental agreements or deeds on behalf of the Company and to do all such things and take all such actions as he/she may consider necessary or desirable for the purpose of giving effect to the Procurement Framework Agreement and completing the transactions contemplated thereunder with such changes as he/she may consider necessary,

797,894,755 (99.999916%)

672 (0.000084%)

desirable or expedient.

As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

2.

To consider and, if thought fit, to approve the appointment of Mr. Liu Yong as an executive director of the fourth session of the Board, and to authorize the chairman of the Board or any executive director of the Company to enter into the service contract or such other documents or supplemental agreements or deeds with him.

2,344,537,054 (99.259196%)

17,498,050 (0.740804%)

As more than 50% of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.

As at the date of the EGM, the total number of issued shares of the Company was 2,767,095,089 shares.

In accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), China National Pharmaceutical Group Corporation and its associates holding an aggregate of 1,574,284,349 shares, representing approximately 56.89% of the total issued share capital of the Company, abstained from voting on the resolution no. 1 proposed at the EGM. Accordingly, the total number of shares entitling the holders to attend and vote for or against the resolution no. 1 was 1,192,810,740 shares, and the total number of shares entitling the holders to attend and vote for or against the resolution no. 2 was 2,767,095,089 shares.

There were no shares entitling the holders to attend and vote only against the resolutions proposed at the EGM and save as disclosed above, there were no restrictions on any shareholder casting votes on the resolutions proposed at the EGM. No party had stated its intention in the circular of the Company dated 3 November 2017 and the supplemental notice of the Company dated 1 December 2017 to vote against the resolutions proposed at the EGM or to abstain from voting.

Shareholders and authorized proxies holding an aggregate of 2,372,179,776 shares, representing 85.73% of the total issued share capital of the Company, were present at the EGM. The holding of the EGM was in compliance with the requirements of the Company Law of the PRC and the articles of association of the Company. The EGM was chaired by Mr. Li Zhiming, the Chairman of the Board.

In compliance with the requirements of the Listing Rules, Computershare Hong Kong Investor Services Limited, the H share registrar of the Company, acted as scrutineer for the vote-taking at the EGM.

By order of the Board of

Sinopharm Group Co. Ltd.

Li Zhiming Chairman

Shanghai, the PRC

18 December 2017

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. She Lulin, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Deng Jindong, Mr. Li Dongjiu, Mr. Lian Wanyong and Mr. Wen Deyong; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong and Mr. Zhuo Fumin.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies

Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

Sinopharm Group Co. Ltd. published this content on 18 December 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 18 December 2017 04:29:03 UTC.

Original documenthttp://sinopharm.todayir.com/attachment/2017121812170100003001776_en.pdf

Public permalinkhttp://www.publicnow.com/view/0CDA2DA1BCBEC9A48D7E7C69EB6E37E75AD1EAC9